{
  "slug": "torpedo-therapeutics",
  "name": "Torpedo Therapeutics",
  "yc_id": 25864,
  "batch": "Winter 2022",
  "website": "https://www.torpedotherapeutics.com",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:14:15.507428",
    "website": "https://www.torpedotherapeutics.com",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 3833.29,
      "final_url": "https://www.torpedotherapeutics.com/",
      "redirected": true,
      "checked_at": "2025-10-17T01:14:19.340735"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "torpedotherapeutics.com",
      "registrar": "Bluehost Inc.",
      "creation_date": "2022-01-13T15:49:47",
      "expiration_date": "2026-01-13T15:49:47",
      "domain_age_days": 1372,
      "domain_age_years": 3.8,
      "name_servers": [
        "NS1.BLUEHOST.COM",
        "NS2.BLUEHOST.COM"
      ]
    },
    "social_links": {
      "twitter": null,
      "linkedin": null,
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": false,
      "content_security_policy": false,
      "x_frame_options": false,
      "x_content_type_options": false,
      "x_xss_protection": false,
      "referrer_policy": false,
      "security_score": 0,
      "server": "Apache"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:38:52.839348",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0",
    "model_used": "google/gemini-2.0-flash-001",
    "enriched_at": "2025-10-17T12:42:06.082135",
    "status": "success",
    "market_analysis": {
      "market_size": "large",
      "market_stage": "growing",
      "key_trends": [
        "Increased prevalence of neurological disorders",
        "Advancements in neurotechnology and AI",
        "Growing demand for personalized and targeted therapies"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Proprietary closed-loop neuromodulation technology and intellectual property.",
      "differentiation": "High-precision, closed-loop system offering personalized and adaptive neuromodulation compared to traditional open-loop DBS.",
      "competitive_advantages": [
        "Improved efficacy and reduced side effects",
        "Potential for broader applications beyond existing DBS indications"
      ],
      "competitive_vulnerabilities": [
        "High regulatory hurdles and clinical trial costs",
        "Competition from established medical device companies"
      ]
    },
    "business_model": {
      "revenue_model": "Hardware (device sales) and potentially recurring revenue from software/data analytics.",
      "scalability": "medium",
      "capital_intensity": "high"
    },
    "growth_assessment": {
      "growth_stage": "seed",
      "growth_indicators": [
        "Successful preclinical and clinical trials",
        "FDA approval and market adoption"
      ],
      "growth_bottlenecks": [
        "Regulatory approval timelines",
        "Manufacturing and scaling production"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "medium",
      "overall_risk_score": 7,
      "key_risks": [
        "Clinical trial failures",
        "Regulatory delays or rejection",
        "Competition from alternative therapies"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Innovative technology with potential to transform neuromodulation",
        "Large and growing market for neurological disorders",
        "Strong team with expertise in neuroscience and engineering"
      ],
      "concerns": [
        "High capital requirements and long development timelines",
        "Regulatory and reimbursement uncertainties"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Medtronic",
        "Boston Scientific"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Secure funding for clinical trials",
        "Strengthen intellectual property portfolio"
      ],
      "expansion_opportunities": [
        "Explore new applications for neuromodulation technology",
        "Develop partnerships with pharmaceutical companies"
      ]
    },
    "tokens_used": {
      "prompt": 678,
      "completion": 613,
      "total": 1291,
      "estimated_cost": 0.000235
    }
  },
  "phase8_complete": true
}